Novel ‘prodrug’ designed to eliminate cancer without harming healthy cells
US researchers discovered in a study in mice that augmented drug eliminates cancer cells without causing toxicity.
List view / Grid view
US researchers discovered in a study in mice that augmented drug eliminates cancer cells without causing toxicity.
US researchers find that bacteria could help tumours progress and resist treatment.
Sloan Kettering Institute (SKI) researchers have developed a new machete technique to slice into the cancer genome and study copy number alterations.
US scientists, using CRISPR technology, removed specific genes in humans to allow the immune system to be more activated against cancer.
Researchers have found peptides that bind to chains of ubiquitin proteins in cancer cells, suggesting they could be used as a therapeutic strategy.
Researchers have developed a new method for comparing CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer.
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
UPF and John Hopkins scientists have discovered how cancer cells exposed to high viscosity environments change their movements to improve their invasiveness and favour metastases.
Spanish researchers have discovered that vitamin C may hold the key to improving the efficacy of dendritic cell-derived anticancer therapies.
In the production of RNA, researchers in Spain and Denmark have found a method for attacking cancer cells.
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
Scientists have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.